XML 74 R21.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2017
Income Tax Disclosure [Abstract] |
Income Taxes |
12. | Income Taxes
The components of loss before income taxes are as follows (in thousands):
|  | Years Ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Domestic |  | $ | (101,234 | ) |  | $ | (38,156 | ) |  | $ | (66,411 | )
Foreign |  |  | (24,648 | ) |  |  | (23,595 | ) |  |  | (19,126 | )
Loss before provision for income taxes |  | $ | (125,882 | ) |  | $ | (61,751 | ) |  | $ | (85,537 | )
The provision for (benefit from) income taxes consists of the following (in thousands):
|  | Years Ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Current: |  |  |  |  |  |  |  |  |  |  |  |
Federal |  | $ | — |  |  | $ | — |  |  | $ | — |
State |  |  | 2 |  |  |  | 2 |  |  |  | 2 |
Foreign |  |  | 319 |  |  |  | 139 |  |  |  | 240 |
Total current |  | $ | 321 |  |  | $ | 141 |  |  | $ | 242 |
Deferred: |  |  |  |  |  |  |  |  |  |  |  |
Federal |  | $ | — |  |  | $ | (212 | ) |  | $ | — |
State |  |  | — |  |  |  | — |  |  |  | — |
Foreign |  |  | — |  |  |  | — |  |  |  | — |
Total deferred |  | $ | — |  |  | $ | (212 | ) |  | $ | — |
Total provision for (benefit from) income taxes |  | $ | 321 |  |  | $ | (71 | ) |  | $ | 242 |
The following is the reconciliation between the statutory federal income tax rate and the Company’s effective tax rate:
| Years Ended December 31, |
| 2017 |  |  | 2016 |  |  | 2015 |
Tax at statutory federal rate |  | 34.0 | % |  |  | 34.0 | % |  |  | 34.0 | %
State tax |  | — | % |  |  | — | % |  |  | — | %
Stock-based compensation expense |  | 18.5 | % |  |  | (7.9 | )% |  |  | (4.6 | )%
Change in deferred tax assets due to rate change |  | 43.9 | % |  |  | — | % |  |  | — | %
Change in valuation allowance due to rate change |  | (43.9 | )% |  |  | — | % |  |  | — | %
Net operating losses not benefitted |  | (43.8 | )% |  |  | (12.9 | )% |  |  | (21.7 | )%
Foreign net operating losses benefitted |  | (6.7 | )% |  |  | (13.0 | )% |  |  | (7.6 | )%
Orphan drug credit |  | (2.0 | )% |  |  | — | % |  |  | — | %
Other |  | (0.3 | )% |  |  | (0.1 | )% |  |  | (0.4 | )%
Total |  | (0.3 | )% |  |  | 0.1 | % |  |  | (0.3 | )%
Significant components of the Company’s deferred tax assets are as follows (in thousands):
|  | December 31, |
|  | 2017 |  |  | 2016 |
Federal and state net operating loss carryforwards |  | $ | 71,256 |  |  | $ | 42,900 |
Tax credit carryforwards |  |  | 39,488 |  |  |  | 29,846 |
Foreign net operating loss carryforwards |  |  | 15,052 |  |  |  | 11,704 |
Stock-based compensation |  |  | 7,835 |  |  |  | 11,231 |
Lease obligations |  |  | 2,737 |  |  |  | 4,414 |
Reserves and accruals |  |  | 4,851 |  |  |  | 5,465 |
Deferred revenue |  |  | 18,103 |  |  |  | 22,909 |
Other |  |  | 420 |  |  |  | 741 |
Subtotal |  |  | 159,742 |  |  |  | 129,210 |
Less: Valuation allowance |  |  | (159,540 | ) |  |  | (128,995 | )
Net deferred tax assets |  |  | 202 |  |  |  | 215 |
Fixed assets |  |  | (181 | ) |  |  | (122 | )
Other |  |  | (21 | ) |  |  | (93 | )
Net deferred tax liabilities |  |  | (202 | ) |  |  | (215 | )
Total net deferred tax assets |  | $ | — |  |  | $ | — |
A valuation allowance has been provided to reduce the deferred tax assets to an amount management believes is more likely than not to be realized. Expected realization of the deferred tax assets for which a valuation allowance has not been recognized is based on upon the reversal of existing temporary differences and future taxable income. The valuation allowance increased by $30.5 million, $12.3 million and $22.0 million for the years ended December 31, 2017, 2016 and 2015, respectively. Due to uncertainty surrounding the realization of the favorable tax attributes in the future tax returns, the Company has established a valuation allowance against its otherwise recognizable net deferred tax assets. At December 31, 2017, the Company had net operating loss carryforwards available to offset future taxable income of approximately $306.0 million and $143.4 million for federal and state tax purposes, respectively. These carryforwards will begin to expire in 2026 for federal and 2018 for state purposes, if not utilized before these dates. The Company also had foreign net operating loss carryforwards of approximately $63.5 million which expire between 2018 and 2027 if not utilized. At December 31, 2017, the Company had approximately $38.8 million of federal and $22.9 million of California research and development tax credit and other tax credit carryforwards available to offset future taxable income. The federal credits begin to expire in 2018 and the California research credits have no expiration dates. On December 22, 2017, the Tax Cuts and Jobs Act (“Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as. The Company has calculated its best estimate of the impact of the Tax Act in accordance with our understanding of the Tax Act and guidance available as of the issuance of the consolidated financial statements. The tax rate decrease resulted in a reduction of $55.2 million in the Company’s deferred tax assets, and a corresponding decrease of the same amount in the valuation allowance against these deferred tax assets, as substantially all of the Company’s U.S. and foreign deferred tax assets, net of deferred tax liabilities, are subject to a full valuation allowance. Due to the adoption of ASU 2016-09 in 2017, the Company recorded a retrospective increase of $19.5 million in the deferred tax assets for previously unrecognized excess tax benefits that existed as of December 31, 2016, and a corresponding increase of $19.5 million in the valuation allowance against these deferred tax assets. In addition, all excess tax benefits and deficiencies are recognized as income tax expense and will result in increased volatility in the Company’s income tax. Federal and state tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an “ownership change” for tax purposes, as defined in IRC Section 382. The Company reviewed its stock ownership for year ended December 31, 2017 and concluded no ownership changes occurred which would result in a reduction of its net operating loss or in its research and development credits expiring unused. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced. Uncertain Tax Positions The Company had unrecognized tax benefits of approximately $23.3 million as of December 31, 2017. Approximately $0.4 million of unrecognized tax benefits, if recognized, would affect the effective tax rate. The interest accrued as of December 31, 2017 and 2016 was immaterial. A reconciliation of the beginning and ending amounts of unrecognized income tax benefits during the three years ended December 31, 2017 is as follows (in thousands):
|  | Federal and State |
Balance as of December 31, 2014 |  | $ | 19,122 |
Decrease due to prior positions |  |  | (2,382 | )
Increase due to current year position |  |  | 7,473 |
Balance as of December 31, 2015 |  |  | 24,213 |
Decrease due to prior positions |  |  | (7,109 | )
Increase due to current year position |  |  | 2,550 |
Balance as of December 31, 2016 |  |  | 19,654 |
Increase due to prior positions |  |  | 303 |
Increase due to current year position |  |  | 5,448 |
Decrease due to U.S. tax rate change |  |  | (2,044 | )
Balance as of December 31, 2017 |  | $ | 23,361 |
Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company’s effective tax rate. The Company classifies interest and penalties as a component of tax expense, if any. The Company files income tax returns in the U.S. federal jurisdiction, U.S. state and other foreign jurisdictions. The U.S. federal and U.S. state taxing authorities may choose to audit tax returns for tax years beyond the statute of limitation period due to significant tax attribute carryforwards from prior years, making adjustments only to carryforward attributes. The foreign statute of limitation generally remains open from 2008 to 2017. The Company is not currently under audit in any tax jurisdiction.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -URI http://asc.fasb.org/topic&trid=2144680 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration